Sodium-Glucose Cotransporter-2 (SGLT-2) Attenuates Serum Uric Acid (SUA) Level in Patients with Type 2 Diabetes
Background. Hyperuricemia has a strong association with diabetes mellitus. Hyperuricemia can lead to cardiovascular and renal complications in patients with diabetes. The goal of this study was to compare the effect of sodium-glucose cotransporter-2 (SGLT-2) inhibitors dapagliflozin and empagliflozi...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | Journal of Diabetes Research |
| Online Access: | http://dx.doi.org/10.1155/2021/9973862 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561438534664192 |
|---|---|
| author | Mazhar Hussain Asim Elahi Abid Hussain Javed Iqbal Lubna Akhtar Abdul Majid |
| author_facet | Mazhar Hussain Asim Elahi Abid Hussain Javed Iqbal Lubna Akhtar Abdul Majid |
| author_sort | Mazhar Hussain |
| collection | DOAJ |
| description | Background. Hyperuricemia has a strong association with diabetes mellitus. Hyperuricemia can lead to cardiovascular and renal complications in patients with diabetes. The goal of this study was to compare the effect of sodium-glucose cotransporter-2 (SGLT-2) inhibitors dapagliflozin and empagliflozin on serum uric acid (SUA) levels in patients with type 2 diabetes against traditional oral antihyperglycemic drugs (OADs). Methods. In this double-blind randomized controlled trial, 70 patients with type 2 diabetes and elevated SUA levels were assigned to two treatment groups. Patients in group A received SGLT-2 inhibitors tablet dapagliflozin 5 mg to 10 mg and empagliflozin 10 mg to 25 mg. Group B patients received OADs such as glimepiride, metformin, sitagliptin, gliclazide, and glibenclamide as monotherapy or combination therapy. The changes in SUA level were primary end points while changes in body weight and body mass index (BMI) from baseline to end point were secondary end points. Results. After four weeks of treatment, we noted a significant reduction of mean SUA levels in the SGLT-2 inhibitor group from 7.5±2.5 to 6.3±0.8 mg/dl versus comparator group from 7.1±1.8 to 6.8±2.2 mg/dl (p=0.001). Mean body weight was significantly reduced in the SGLT-2 group from 82±10.4 to 78±12.5 kg versus comparator group from 78±13.2 to 79.2±9.7 kg (p=0.001). Similarly, the mean BMI of patients in the SGLT-2 group was significantly reduced from 25.7±3.2 to 24.2±3.2 kg/m2 versus comparator group from 27.5±4.2 to 28±3.6 kg/m2 (p=0.002). Conclusion. SGLT-2 inhibitors have a strong potential to decrease SUA levels in patients with type 2 diabetes. |
| format | Article |
| id | doaj-art-84f4a3453e4a4b8fb9a668072f600968 |
| institution | Kabale University |
| issn | 2314-6745 2314-6753 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Diabetes Research |
| spelling | doaj-art-84f4a3453e4a4b8fb9a668072f6009682025-02-03T01:25:07ZengWileyJournal of Diabetes Research2314-67452314-67532021-01-01202110.1155/2021/99738629973862Sodium-Glucose Cotransporter-2 (SGLT-2) Attenuates Serum Uric Acid (SUA) Level in Patients with Type 2 DiabetesMazhar Hussain0Asim Elahi1Abid Hussain2Javed Iqbal3Lubna Akhtar4Abdul Majid5Department of Pharmacology & Therapeutics Sheikh Zayed Medical College/Hospital, Rahim Yar Khan, Punjab, PakistanDepartment of Medicine CHI Saint Joseph Health Hospital, London, Kentucky, USADepartment of Nephrology Sheikh Zayed Medical College/Hospital, Rahim Yar Khan, PakistanDepartment of Medicine Sheikh Zayed Medical College/Hospital, Rahim Yar Khan, PakistanDepartment of Pharmacology & Therapeutics Sheikh Zayed Medical College/Hospital, Rahim Yar Khan, Punjab, PakistanDepartment of Cardiology, Sheikh Zayed Medical College & Hospital Rahim Yar Khan, PakistanBackground. Hyperuricemia has a strong association with diabetes mellitus. Hyperuricemia can lead to cardiovascular and renal complications in patients with diabetes. The goal of this study was to compare the effect of sodium-glucose cotransporter-2 (SGLT-2) inhibitors dapagliflozin and empagliflozin on serum uric acid (SUA) levels in patients with type 2 diabetes against traditional oral antihyperglycemic drugs (OADs). Methods. In this double-blind randomized controlled trial, 70 patients with type 2 diabetes and elevated SUA levels were assigned to two treatment groups. Patients in group A received SGLT-2 inhibitors tablet dapagliflozin 5 mg to 10 mg and empagliflozin 10 mg to 25 mg. Group B patients received OADs such as glimepiride, metformin, sitagliptin, gliclazide, and glibenclamide as monotherapy or combination therapy. The changes in SUA level were primary end points while changes in body weight and body mass index (BMI) from baseline to end point were secondary end points. Results. After four weeks of treatment, we noted a significant reduction of mean SUA levels in the SGLT-2 inhibitor group from 7.5±2.5 to 6.3±0.8 mg/dl versus comparator group from 7.1±1.8 to 6.8±2.2 mg/dl (p=0.001). Mean body weight was significantly reduced in the SGLT-2 group from 82±10.4 to 78±12.5 kg versus comparator group from 78±13.2 to 79.2±9.7 kg (p=0.001). Similarly, the mean BMI of patients in the SGLT-2 group was significantly reduced from 25.7±3.2 to 24.2±3.2 kg/m2 versus comparator group from 27.5±4.2 to 28±3.6 kg/m2 (p=0.002). Conclusion. SGLT-2 inhibitors have a strong potential to decrease SUA levels in patients with type 2 diabetes.http://dx.doi.org/10.1155/2021/9973862 |
| spellingShingle | Mazhar Hussain Asim Elahi Abid Hussain Javed Iqbal Lubna Akhtar Abdul Majid Sodium-Glucose Cotransporter-2 (SGLT-2) Attenuates Serum Uric Acid (SUA) Level in Patients with Type 2 Diabetes Journal of Diabetes Research |
| title | Sodium-Glucose Cotransporter-2 (SGLT-2) Attenuates Serum Uric Acid (SUA) Level in Patients with Type 2 Diabetes |
| title_full | Sodium-Glucose Cotransporter-2 (SGLT-2) Attenuates Serum Uric Acid (SUA) Level in Patients with Type 2 Diabetes |
| title_fullStr | Sodium-Glucose Cotransporter-2 (SGLT-2) Attenuates Serum Uric Acid (SUA) Level in Patients with Type 2 Diabetes |
| title_full_unstemmed | Sodium-Glucose Cotransporter-2 (SGLT-2) Attenuates Serum Uric Acid (SUA) Level in Patients with Type 2 Diabetes |
| title_short | Sodium-Glucose Cotransporter-2 (SGLT-2) Attenuates Serum Uric Acid (SUA) Level in Patients with Type 2 Diabetes |
| title_sort | sodium glucose cotransporter 2 sglt 2 attenuates serum uric acid sua level in patients with type 2 diabetes |
| url | http://dx.doi.org/10.1155/2021/9973862 |
| work_keys_str_mv | AT mazharhussain sodiumglucosecotransporter2sglt2attenuatesserumuricacidsualevelinpatientswithtype2diabetes AT asimelahi sodiumglucosecotransporter2sglt2attenuatesserumuricacidsualevelinpatientswithtype2diabetes AT abidhussain sodiumglucosecotransporter2sglt2attenuatesserumuricacidsualevelinpatientswithtype2diabetes AT javediqbal sodiumglucosecotransporter2sglt2attenuatesserumuricacidsualevelinpatientswithtype2diabetes AT lubnaakhtar sodiumglucosecotransporter2sglt2attenuatesserumuricacidsualevelinpatientswithtype2diabetes AT abdulmajid sodiumglucosecotransporter2sglt2attenuatesserumuricacidsualevelinpatientswithtype2diabetes |